A toxin from rattlesnake venom
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Product Categories

Product Type

Convulxin

Item No. 19082

Technical Information
CAS Number
37206-04-5
MW
~84 kDa
A solid
HEPES Buffer: Soluble
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Product Description

    Convulxin is a toxin that was first isolated from rattlesnake venom. It activates the collagen receptor glycoprotein VI (GPVI) on platelets and initiates blood clotting.1,2 Convulxin is used to study signaling through GPVI and to characterize platelet function.3,4,5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Vargaftig, B.B., Prado-Francheschi, J., Chignard, M., et alActivation of guinea-pig platelets induced by convulxin, a substance extracted from the venom of Crotalus durissus cascavella. Eur. J. Pharmacol. 68(4), 451-464 (2016).

    2. Jandrot-Perrus, M., Lagrue, A.H., Okuma, M., et alAdhesion and activation of human platelets induced by convulxin involve glycoprotein VI and integrin α2β1. The Journal of Biological Chemisty 272(43), 27035-27041 (1997).

    3. Chatterjee, M.S., Denney, W.S., Jing, H., et alSystems biology of coagulation initiation: Kinetics of thrombin generation in resting and activated human blood. PLoS Comput. Biol. 6(9), (2010).

    4. Casari, C., Berrou, E., Lebret, M., et alvon Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3. J. Clin. Invest. 123(12), 5071-5081 (2013).

    5. van Bladel, E.R., Laarhoven, A.G., van der Heijden, L.B., et alFunctional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts. Blood 123(10), 1556-1563 (2014).